Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy

Figures & data

Table 1. Determination of HA decoration.

HA dosage (mg)	Zeta potential (mV)	EE of BCL (%)	EE of DOX (%)
0	+21.7 ± 2.1	91.5 ± 1.9	92.3 ± 1.6
100	+18.9 ± 1.9	91.3 ± 2.1	91.6 ± 1.7
200	+15.1 ± 1.7	90.9 ± 1.7	91.3 ± 1.6
300	+12.6 ± 1.2	90.6 ± 1.5	91.5 ± 2.1
400	+11.9 ± 1.6	67.5 ± 4.5	88.6 ± 3.1
500	+11.8 ± 1.9	55.1 ± 6.9	69.2 ± 5.4

Table 2. Physicochemical characterization of different NLCs complexes.

Samples	Particle size (nm)	Zeta potential (mV)	EE of BCL (%)	EE of DOX (%)
NLCs	78.5 ± 1.9	+31.5 ± 2.8	N/A	N/A
BCL-NLCs	86.2 ± 2.1	+27.1 ± 2.6	92.1 ± 1.6	N/A
DOX-NLCs	88.1 ± 1.8	+25.9 ± 2.3	N/A	92.5 ± 1.8
BCL/DOX-NLCs	89.7 ± 1.9	+21.5 ± 1.9	91.9 ± 1.8	91.7 ± 2.1
HA-BCL/DOX-NLCs	103.5 ± 2.2	+12.6 ± 1.2	90.8 ± 1.7	91.5 ± 1.8

Figure 1. Drug release profiles of NLCs formulations in vitro. (a) BCL release of BCL/DOX-NLCs, (b) BCL release of HA-BCL/DOX-NLCs, (c) DOX release of BCL/DOX-NLCs and (d) DOX release of HA-BCL/DOX-NLCs.

Table 3. IC₅₀ and CI₅₀ values of drugs solutions and NLCs on MCF-7/ADR cells.

Samples	IC50 of BCL (μg/mL)	IC50 of DOX (μg/mL)	CI50
BCL	0.876	N/A	N/A
DOX	N/A	6.271	N/A
BCL/DOX solution	0.662	0.331	0.808
BCL-NLCs	0.178	N/A	N/A
DOX-NLCs	N/A	1.147	N/A
BCL/DOX-NLCs	0.126	0.063	0.763
HA-BCL/DOX-NLCs	0.056	0.028	0.339

Figure 2. The tumor growth curves of different formulations in vivo. (a) HA-BCL/DOX-NLCs, (b) BCL/DOX-NLCs, (c) BCL-NLCs, (d) DOX-NLCs, (e) BCL/DOX solution and (f) 0.9% saline.